TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
Life Sciences & Drug Development · Baumol's cost disease drives pharma R&D inflation; removing humans from labs is the only cure
now playing · Life Sciences & Drug Development
AI Infrastructuretailwindscore 9/10jason kelly
Autonomous labs will 10-100x scientific discovery speed by replacing human bench work
AI reasoning models combined with fully robotic 'autonomous labs' can run experimental cycles 24/7, share data instantly across 100+ parallel AI scientists, and shift R&D spend from overhea…
AI Drug Discoverytailwindscore 8/10jason kelly
Protein and genomic foundation models are delivering near-term commercial deals in pharma
AI models for protein design (Chai Bio) and genomic modeling (Arc Institute's Evo 2) are already securing major partnerships (e.g., Chai-Lilly), proving that the 'front end' of AI-driven dr…
Advanced Manufacturingtailwindscore 8/10jason kelly
High-mix, low-volume lab automation is an engineering problem now tractable via AI
Lab automation has been stuck at 'subway' levels (low mix, high volume) but AI enables 'Waymo-level' autonomy — handling the thousand-device integration and liquid-handling edge cases that…
AI Geopolitics & Export Controlsriskscore 8/10jason kelly
China's rise in experimental science capacity threatens US leadership; AI+automation is the counter
China now publishes more scientific papers and captures 40%+ of biotech licensing deals (up from <5% three years ago) due to more experimentalists at lower cost; the US must adopt AI-driven…
Life Sciences & Drug Developmentheadwindscore 8/10jason kelly
Baumol's cost disease drives pharma R&D inflation; removing humans from labs is the only cure
Drug development costs have risen for 25 years because the dominant expenses (scientists, lab space, overhead) are labor-intensive and don't scale; only full automation of experimental work…
GLP-1 & Metabolic Drugstailwindscore 8/10jason kelly
GLP-1 drugs are consumer products worth trillions, not just disease treatments
GLP-1 agonists represent a shift from treating disease to enhancing healthy human traits (weight, appetite control), creating a consumer biotech market potentially worth $50T+ if lifespan-e…
Government Technologytailwindscore 7/10jason kelly
Project Genesis: DOE deploys autonomous labs at national labs to double science velocity
The Department of Energy's Project Genesis — backed by the White House OSTP — is installing Ginkgo's autonomous lab systems at national labs to accelerate strategic science (materials, ener…
AI Economics & Business Modelsmixedscore 7/10jason kelly
AI-driven science will lower creation costs but intensify distribution competition, reshaping venture
As AI and autonomous labs slash the cost of scientific creation, the venture model will mirror the cloud transition: explosion in company formation but fierce competition for attention and…
Longevity & Agingtailwindscore 7/10jason kelly
Molecular-level longitudinal monitoring will enable personalized longevity interventions
Weekly blood-based molecular profiling (as pioneered by Bryan Johnson) will replace wearables as the primary health data layer, allowing individuals to test interventions and measure aging…
AI Applicationstailwindscore 7/10jason kelly
Cloud labs at $39/experiment could democratize science like PCs democratized computing
Ginkgo's new cloud lab service (Igen) offers remote robotic experiments starting at $39 with data-only return, potentially enabling millions of 'citizen scientists' to run real experiments…